Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 12,226 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Alzheimer's Disease
Interventions: BPN14770, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 25 Years to 90 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Non-Alcoholic Steatohepatitis
Interventions: SHP626, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Breast Carcinoma
Interventions: Best Practice, Discussion, Interview - Stakeholder, Interview - Key Informant, Interview - Ancillary studies, Patient Navigation - C Components, Patient Navigation - B components, Patient Navigation - A components, Survey Administration, Survey Administration - Ancillary studies; Other · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Zidovudine, Sargramostim, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: 23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 20
States / cities: Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more

Conditions: Cirrhosis, Liver, Portal Hypertension
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Degenerative Disc Disease
Interventions: MagnetOs Flex Matrix; Device
Lead sponsor: Research Source; Network
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Southfield, Michigan

Conditions: Osteoarthritis
Interventions: GSK3196165, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Miami, Florida • Duncansville, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Melphalan; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Birmingham, Alabama • New York, New York • Charleston, South Carolina + 1 more

Conditions: Multiple Sclerosis
Interventions: Avonex (Interferon beta 1a), Riluzole, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Atazanavir, Atazanavir/Ritonavir, Atazanavir/Ritonavir+Omeprazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Hamilton, New Jersey

Conditions: Clostridium Difficile Infection Recurrence
Interventions: RBX2660; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more

Conditions: Cognitive Disorders
Interventions: SUVN-D4010, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Dyslipidemia
Interventions: BMS-823778, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Little Rock, Arkansas • Lenexa, Kansas • Cincinnati, Ohio + 3 more

Conditions: Diabetic Foot Ulcer, Diabetic Foot
Interventions: Medaxis Debritom+, Sharp Surgical Debridement, Additional Outer Dressing Application, Offloading, Fibracol Wound Dressing; Other
Lead sponsor: Medaxis, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 6
States / cities: San Francisco, California • South Miami, Florida • Frederick, Maryland + 3 more

Conditions: Alzheimer Disease
Interventions: bapineuzumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 16
States / cities: Phoenix, Arizona • Encino, California • Delray Beach, Florida + 11 more

Conditions: Actinic Keratoses
Interventions: Diclofenac Sodium Gel, Solaraze 3% Topical Gel, Placebo; Drug · Other
Lead sponsor: Encube Ethicals Pvt. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 24
States / cities: Bryant, Arkansas • San Ramon, California • Coral Gables, Florida + 20 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol, Placebo, Methotrexate; Biological · Other
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more

Conditions: Trisomy 13, Trisomy 18, Trisomy 21, Aneuploidy
Interventions: Blood Draw; Procedure
Lead sponsor: Natera, Inc.; Industry
Eligibility: Female only
Enrollment: 937 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2023
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndrome, Childhood Renal Cell Carcinoma, Chronic Myelomonocytic Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndrome, Metastatic Renal Cell Cancer, Previously Treated Myelodysplastic Syndrome, Progression of Multiple Myeloma or Plasma Cell Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Renal Medullary Carcinoma, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil; Drug · Radiation · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 8
States / cities: Tucson, Arizona • Stanford, California • Atlanta, Georgia + 5 more

Conditions: Ischemic Stroke, Malignant Edema
Interventions: Glyburide for Injection, Placebo; Drug
Lead sponsor: Remedy Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 17
States / cities: Tucson, Arizona • Stanford, California • New Haven, Connecticut + 14 more

Conditions: Ovarian Cancer
Interventions: BSI-201; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: fenretinide; Drug
Lead sponsor: California Cancer Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more

Search by objective public record fields.

A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study

Study to Assess the Performance of MagnEtOs Flex Matrix Compared to Cellular Allograft

A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

Drug Interaction Study With Proton Pump Inhibitor

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial

Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells

Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer